GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00362585 | Oral cavity | OSCC | multivesicular body assembly | 28/7305 | 30/18723 | 5.89e-10 | 1.52e-08 | 28 |
GO:00070327 | Oral cavity | OSCC | endosome organization | 59/7305 | 82/18723 | 1.41e-09 | 3.39e-08 | 59 |
GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
GO:19019875 | Oral cavity | OSCC | regulation of cell cycle phase transition | 209/7305 | 390/18723 | 2.79e-09 | 6.42e-08 | 209 |
GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:00069974 | Oral cavity | OSCC | nucleus organization | 85/7305 | 133/18723 | 5.12e-09 | 1.12e-07 | 85 |
GO:005212620 | Oral cavity | OSCC | movement in host environment | 106/7305 | 175/18723 | 5.84e-09 | 1.26e-07 | 106 |
GO:00325065 | Oral cavity | OSCC | cytokinetic process | 33/7305 | 39/18723 | 5.91e-09 | 1.26e-07 | 33 |
GO:00717633 | Oral cavity | OSCC | nuclear membrane organization | 29/7305 | 33/18723 | 8.40e-09 | 1.76e-07 | 29 |
GO:190121420 | Oral cavity | OSCC | regulation of neuron death | 174/7305 | 319/18723 | 1.09e-08 | 2.23e-07 | 174 |
GO:00002815 | Oral cavity | OSCC | mitotic cytokinesis | 51/7305 | 71/18723 | 2.01e-08 | 3.95e-07 | 51 |
GO:00719855 | Oral cavity | OSCC | multivesicular body sorting pathway | 31/7305 | 37/18723 | 2.80e-08 | 5.41e-07 | 31 |
GO:00069982 | Oral cavity | OSCC | nuclear envelope organization | 37/7305 | 47/18723 | 3.19e-08 | 6.12e-07 | 37 |
GO:00000753 | Oral cavity | OSCC | cell cycle checkpoint | 101/7305 | 169/18723 | 3.53e-08 | 6.68e-07 | 101 |
GO:00070933 | Oral cavity | OSCC | mitotic cell cycle checkpoint | 81/7305 | 129/18723 | 3.75e-08 | 7.06e-07 | 81 |
GO:00325096 | Oral cavity | OSCC | endosome transport via multivesicular body sorting pathway | 27/7305 | 31/18723 | 4.29e-08 | 8.03e-07 | 27 |
GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHM | SNV | Missense_Mutation | rs746300399 | c.10N>G | p.Thr4Ala | p.T4A | P24386 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
CHM | SNV | Missense_Mutation | | c.741N>G | p.Ile247Met | p.I247M | P24386 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CHM | SNV | Missense_Mutation | | c.1462C>T | p.Arg488Trp | p.R488W | P24386 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHM | SNV | Missense_Mutation | | c.158N>T | p.Ser53Leu | p.S53L | P24386 | protein_coding | deleterious(0.01) | benign(0.408) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
CHM | SNV | Missense_Mutation | | c.1093C>A | p.Leu365Ile | p.L365I | P24386 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHM | SNV | Missense_Mutation | novel | c.888G>A | p.Met296Ile | p.M296I | P24386 | protein_coding | deleterious(0.02) | possibly_damaging(0.551) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
CHM | SNV | Missense_Mutation | novel | c.1061N>A | p.Gly354Asp | p.G354D | P24386 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CHM | SNV | Missense_Mutation | novel | c.180N>T | p.Lys60Asn | p.K60N | P24386 | protein_coding | deleterious(0.04) | benign(0.02) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CHM | SNV | Missense_Mutation | | c.677G>T | p.Arg226Ile | p.R226I | P24386 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CHM | SNV | Missense_Mutation | rs780111922 | c.1727N>G | p.Ser576Cys | p.S576C | P24386 | protein_coding | deleterious(0.01) | benign(0.324) | TCGA-Q1-A73S-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |